Drug delivery: Beyond active tumour targeting

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1131-1137

  Sagnella, Sharon M ^a,b   McCarroll, Joshua A ^a,b   Kavallaris, Maria ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug delivery; Nanomedicine; Tumour microenvironment

Indexed keywords

CELL CULTURE; DISEASES; DRUG DELIVERY; ENDOTHELIAL CELLS; ENZYME INHIBITION; MEDICAL NANOTECHNOLOGY;

CHEMOTHERAPY AGENTS; DELIVERY VEHICLE; EXTRACELLULAR MATRICES; MICROENVIRONMENTS; PERSONALISED MEDICINES; THERAPEUTIC AGENTS; THERAPEUTIC DRUGS; TUMOR MICROENVIRONMENT;

TUMORS;

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CIRCULATION TIME; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; IN VITRO STUDY; NANOMEDICINE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SOLID TUMOR; SURFACE PROPERTY; TUMOR CELL; TUMOR MICROENVIRONMENT; VASCULARIZATION; ANIMAL; DRUG EFFECTS; HUMAN; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84905280838     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.04.012     Document Type: Article

References (44)

1. Cho K.J., Wang X., Nie S.M., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
2. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
3. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
4. Farrell D., Ptak K., Panaro N.J., Grodzinski P. Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm Res 2011, 28:273-278.
5. Bisht S., Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:415-425.
6. Lee P.Y., Wong K.K.Y. Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv 2011, 8:245-253.
7. Drummond C.J., Fong C. Surfactant self-assembly objects as novel drug delivery vehicles. Curr Opin Colloid Interface Sci 1999, 4:449-456.
8. Sagnella S.M., Conn C.E., Krodkiewska I., Moghaddam M., Seddon J.M., Drummond C.J. Ordered nanostructured amphiphile self-assembly materials from endogenous nonionic unsaturated monoethanolamide lipids in water. Langmuir 2010, 26:3084-3094.
9. Sagnella S.M., Gong X.J., Moghaddam M.J., Conn C.E., Kimpton K., Waddington L.J., et al. Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents. Nanoscale 2011, 3:919-924.
10. Boyer C., Priyanto P., Davis T.P., Pissuwan D., Bulmus V., Kavallaris M., et al. Anti-fouling magnetic nanoparticles for siRNA delivery. J Mater Chem 2010, 20:255-265.
11. Huang K.Y., Ma H.L., Liu J., Huo S.D., Kumar A., Wei T., et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012, 6:4483-4493.
12. Slowing I.I., Vivero-Escoto J.L., Wu C.W., Lin V.S.Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008, 60:1278-1288.
13. Markovsky E., Baabur-Cohen H., Eldar-Boock A., Omer L., Tiram G., Ferber S., et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012, 161:446-460.
14. Holback H., Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 2011, 28:1819-1830.
15. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
16. Bertrand N., Leroux J.C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release 2012, 161:152-163.
17. Goncalves C., Torrado E., Martins T., Pereira P., Pedrosa J., Gama M. Dextrin nanoparticles: Studies on the interaction with murine macrophages and blood clearance. Colloids Surf B: Biointerfaces 2010, 75:483-489.
18. Cheng M.R., Li Q., Wan T., He B., Han J., Chen H.X., et al. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012, 18:6076-6087.
19. Jiang H.L., Kwon J.T., Kim Y.K., Kim E.M., Arote R., Jeong H.J., et al. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther 2007, 14:1389-1398.
20. Duong H.T.T., Hughes F., Sagnella S., Kavallaris M., Macmillan A., Whan R., et al. Functionalizing biodegradable dextran scaffolds using living radical polymerization: new versatile nanoparticles for the delivery of therapeutic molecules. Mol Pharm 2012, 9:3046-3061.
21. Holgado M.A., Martin-Banderas L., Alvarez-Fuentes J., Fernandez-Arevalo M., Arias J.L. Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules. Curr Med Chem 2012, 19:3188-3195.
22. Basile L., Pignatello R., Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv 2012, 9:255-268.
23. Daniels T.R., Bernabeu E., Rodriguez J.A., Patel S., Kozman M., Chiappetta D.A., et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta Gen Subj 1820, 2012:291-317.
24. Casi G., Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012, 161:422-428.
25. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
26. Saptarshi S.R., Duschl A., Lopata A.L. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnol 2013, 11.
27. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
28. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
29. Feron O. Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med 2010, 2.
30. Alberici L., Roth L., Sugahara K.N., Agemy L., Kotamraju V.R., Teesalu T., et al. De novo design of a tumor-penetrating peptide. Cancer Res 2013, 73:804-812.
31. Goodman T.T., Olive P.L., Pun S.H. Increased nanoparticle penetration in collagenase-treated multicellullar spheroids. Int J Nanomedicine 2007, 2:265-274.
32. Wong C., Stylianopoulos T., Cui J.A., Martin J., Chauhan V.P., Jiang W., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011, 108:2426-2431.
33. Chauhan V.P., Popovic Z., Chen O., Cui J., Fukumura D., Bawendi M.G., et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50:11417-11420.
34. Liu Q., Li R.T., Qian H.Q., Yang M., Zhu Z.S., Wu W., et al. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles. Int J Nanomedicine 2012, 7:281-295.
35. Lu D., Wientjes M.G., Lu Z., Au J.L.S. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007, 322:80-88.
36. Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013, 4:2516.
37. Krupka T.M., Solorio L., Wilson R.E., Wu H.P., Azar N., Exner A.A. Formulation and characterization of echogenic lipid-pluronic nanobubbles. Mol Pharm 2010, 7:49-59.
38. Peiris P.M., Bauer L., Toy R., Tran E., Pansky J., Doolittle E., et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS Nano 2012, 6:4157-4168.
39. Zhang A.L., Mi X.P., Yang G., Xu L.X. Numerical study of thermally targeted liposomal drug delivery in tumor. J Heat Transf Trans Asme 2009, 131.
40. Basuki J.S., Duong H.T., Macmillan A., Erlich R.B., Esser L., Akerfeldt M.C., et al. Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release. ACS Nano 2013, 7:10175-10189.
41. Sagnella S.M., Duong H., MacMillan A., Boyer C., Whan R., McCarroll J.A., et al. Dextran-based Doxorubicin nanocarriers with improved tumor penetration. Biomacromolecules 2014, 15:262-275.
42. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
43. Liang Y., Jeong J., DeVolder R.J., Cha C., Wang F., Tong Y.W., et al. A cell-instructive hydrogel to regulate malignancy of 3D tumor spheroids with matrix rigidity. Biomaterials 2011, 32:9308-9315.
44. Mehta G., Hsiao A.Y., Ingram M., Luker G.D., Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 2012, 164:192-204.